Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer

Driver oncogenic mutations in genes such as EGFR and ALK are currently considered important therapeutic targets in non-small cell lung cancer (NSCLC)[1,2]. Although driver-specific inhibitors have marked treatment effects on tumors with these driver alterations, tumors often develop resistance[3] and thus become difficult to treat. Recent research on immune-checkpoint inhibitor (ICI) immunotherapy has shed light on intractable cases, and ICI therapy has become one of the first-line treatment options of NSCLC without driver mutations[4].

Source: Lung Cancer - January 6, 2020 Category: Cancer & Oncology Authors: Katsuhiro Yoshimura, Yusuke Inoue, Kazuo Tsuchiya, Masato Karayama, Hidetaka Yamada, Yuji Iwashita, Akikazu Kawase, Masayuki Tanahashi, Hiroshi Ogawa, Naoki Inui, Kazuhito Funai, Kazuya Shinmura, Hiroshi Niwa, Takafumi Suda, Haruhiko Sugimura Source Type: research